Resveratrol increases serum adiponectin level and decreases leptin and insulin level in an experimental model of hypercholesterolemia.

Serum adiponectin concentration is inversely associated with leptin and insulin concentration. There is little paucity of information in the literature on the adipokine levels and regulation by resveratrol in cholesterol diet-fed animals. Thirty rabbits were randomly divided into six groups, each of five animals: Group 1 = control (C), Group 2 = cholesterol diet (CD) only, Group 3 = resveratrol 200 mg/kg (R200), Group 4 = resveratrol 400 mg/kg (R400), Group 5 = CD + R200, Group 6 = CD + R400. The preparations were administered for 8th weeks of the treatment protocol. weight and blood glucose level were measured on week zero and the 8th week of the treatment. At the end of the study period, the rabbits were placed under light anaesthesia. Blood samples were evaluated for serum concentrations of metabolites assays (adiponectin, leptin and insulin). Serum adiponectin significantly (P < 0.05) increased in resveratrol + CD groups, compared to CD group only. Leptin and insulin significantly (P <0.05) decreased in CD groups co-administered with resveratrol, compared with CD group only. In conclusion, the increase in adiponectin level and decrease in leptin and insulin level following resveratrol administration elucidated the therapeutic potential of resveratrol, despite cholesterol diet consumption.